Daily BriefsSouth Korea

Daily Brief South Korea: Netmarble , SK Telecom, Dong A St and more

In today’s briefing:

  • Netmarble Is Considering on Issuing EB Worth 250 Billion Won Backed by Its Stake in HYBE
  • Div Tax Intel Drop: Street Pivoting to Forward Yield Plays (Consensus Data Excel Attached)
  • Dong A St (170900 KS): Five Reasons Why Performance Improvement Is Expected


Netmarble Is Considering on Issuing EB Worth 250 Billion Won Backed by Its Stake in HYBE

By Douglas Kim

  • According to the local media, Netmarble is considering on issuing exchangeable bonds (EB) worth about 250 billion won backed by its stake in HYBE.
  • The potential EB issue is likely to be slightly positive on Netmarble and slightly negative on HYBE (mainly due to additional shares that could be sold in the market). 
  • We are Negative on BOTH Netmarble and HYBE. Their valuations are not attractive. Plus, HYBE could face a major negative issue of its founder Bang Si-hyuk who could be jailed. 

Div Tax Intel Drop: Street Pivoting to Forward Yield Plays (Consensus Data Excel Attached)

By Sanghyun Park

  • This is MoEF’s first gov-led tax reform—not lawmaker-initiated—and unlike April’s DP bill, it carries broader scope and priority fast-track status, boosting passage odds.
  • Local chatter says MoEF is eyeing end-July to table its tax reform bill — that’s the base case making the rounds on the tape today.
  • Gov may go full-scope: 9–25% div tax on all firms plus tax credits. Traders are now rotating into high forward-yield names ahead of MoEF’s late-July package.

Dong A St (170900 KS): Five Reasons Why Performance Improvement Is Expected

By Tina Banerjee

  • Dong A St (170900 KS) 1Q25 revenue rose 21% YoY, which is a significant improvement as the company recorded just 6% YoY growth in revenue in 2024.
  • Existing operation of Dong A St is showing strength. Stelara biosimilar to generate sales royalties from this year. Cenobamate launch is expected by next year.
  • Pipeline is promising, with upcoming data readouts expected through 2026. Obesity drug candidate has best-in-class potential.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars